제1그룹
서훈희Ph.D.
주요 연구 키워드
- Mycobacterium tuberculosis
- Microbiome therapeutics
- Microbiome Drug GMP
- Superburgs
Contact
충남 아산시 배방읍 이순신대로 813-26 상용화센터 3층
Research on the development of therapeutics for antibiotic-resistant tuberculosis and other multidrug-resistant superbugs.
Development of microbiome-based therapeutics for the treatment of human diseases.
Process development and GMP-compliant manufacturing of microbiome-based medicinal products.
Insights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis, Cells, 2025
Microbiome therapeutic PMC72 through reverse translational research in gout, Journal of Microbiology, 2025
DNA reference reagents isolate biases in microbiome profiling: a global multi-lab study, mSystems, 2025
In Vivo Therapeutic Potential of Next-Generation Probiotic Akkermansia muciniphila and Butyrate Combination Therapy in Diabetes, Journal of Microbiology & Biotechnology, 2025
Perspectives on Microbiome Therapeutics in Infectious Diseases: A Comprehensive Approach Beyond Immunology and Microbiology, Cells, 2024
Clinical Potential of Novel Microbial Therapeutic LP51 Based on Xerosis-Microbiome Index, Cells, 2024
Clinical effect of Pediococcus acidilactici PMC48 on hyperpigmented skin, Journal of Cosmetic Dermatology, 2024
Synthesis and activity of BNF15 against drug-resistant Mycobacterium tuberculosis, Future Medicinal Chemistry, 2021
Malignant Prostate Tissue Is Associated with Different Microbiome Gene Functions, Diagnostics (Basel), 2023
Antimicrobial activity of IDD-B40 against drug-resistant Mycobacterium tuberculosis, Scientific Reports, 2021